Vycor Medical 5/15/2025 Earnings Report

Vycor Medical EPS Results

• Actual EPS: -$0.01
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Vycor Medical Revenue Results

• Actual Revenue: $0.44 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Vycor Medical Announcement Details

• Date: 5/15/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Vycor Medical (OTCMKTS:VYCO) is a medical device company specializing in the design, development and manufacture of minimally invasive cranial access systems for use in neurosurgery. The company’s proprietary endoport platform is engineered to provide neurosurgeons with controlled, cannula-based access for intracranial procedures such as tumor biopsy, resection and hematoma drainage. By integrating visualization channels and atraumatic retraction technology, Vycor’s products are intended to reduce collateral damage to healthy brain tissue and streamline procedural workflows.

The company’s core portfolio includes its flagship endoport system along with complementary accessories such as obturators, sheaths and closure devices. Its platforms are cleared by the U.S. Food and Drug Administration and carry CE marking for select international markets. Vycor continues to invest in product enhancements and procedural innovations aimed at expanding clinical indications and supporting minimally invasive approaches across a range of neurosurgical specialties.

Founded in 1990 and headquartered in Boca Raton, Florida, Vycor Medical has established a direct‐sales presence in the United States and collaborates with distribution partners in Europe and Asia to broaden its geographic reach. The company works closely with leading medical centers, clinical investigators and key opinion leaders to gather real-world data, refine its technology and drive training initiatives that facilitate adoption of advanced neurosurgical techniques.

Under the leadership of seasoned medtech executives, Vycor Medical maintains a focus on regulatory compliance, quality management and strategic R&D alliances. The company’s ongoing efforts center on leveraging its endoport platform to address unmet clinical needs, support minimally invasive therapy trends and deliver value to physicians, hospitals and patients in the global neurosurgical market.